HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Disclosure Statements An erratum has been published Rapid Responses: Submit a response Alert me when this article is cited Alert me when Rapid Responses are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hinnen, D. Articles by Kushner, P. Search for Related Content PubMed PubMed Citation Articles by Hinnen, D. Articles by Kushner, P.

Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes

Mid America Diabetes Associates (DH), Wichita, KS
Amylin Pharmaceuticals Inc. (LLN), San Diego, CA
Eli Lilly and Company (AW), Indianapolis IN
University of California, Irvine Medical Center (PK), Orange, CA

Correspondence: Corresponding author: Debbie Hinnen, Mid America Diabetes Associates, 200 S. Hillside, Wichita, KS 67211 (E-mail: dhinnen{at}madiabetesa.com)

Incretin mimetics are a new class of pharmacological agents with multiple antihyperglycemic actions that mimic several of the actions of incretin hormones originating in the gut, such as glucagon-like peptide (GLP)-1. Dipeptidyl peptidase-IV (DPP-IV) inhibitors suppress the degradation of many peptides, including GLP-1, thereby extending their bioactivity. These agents seem to have multiple mechanisms of action for the treatment of type 2 diabetes mellitus (T2DM), including some or all the following: enhancement of glucose-dependent insulin secretion, suppression of inappropriately elevated glucagon secretion, slowing of gastric emptying, and decreased food intake. Exenatide (BYETTA®) is the first incretin mimetic approved for clinical use by the US Food and Drug Administration. In phase 3 clinical trials, exenatide reduced HbA_1c by 1% and body weight by 2 kg in T2DM patients failing to achieve glycemic control with metformin and/or a sulfonylurea, with mild-to-moderate nausea the most common side effect. Several GLP-1 analogues and DPP-IV inhibitors are in late-stage clinical testing and may soon become available for treating T2DM patients. The use of these agents may provide an opportunity to bring about new improvements in diabetes care.

This article has been cited by other articles:

				K. J. Miller and A. V. Azzara An Old Dog Learns a New Trick: Regulation of Peripheral Glucose Homeostasis by the Serotonin (5-HT)2C Receptor Mol. Interv., April 1, 2008; 8(2): 73 - 77. [Abstract] [Full Text] [PDF]